Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer
نویسندگان
چکیده
منابع مشابه
Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is the second drug in 40 years to be FDA approved for this indication. Recent reviews and a meta-analy...
متن کاملLenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Management options are limited for patients with radioactive iodine refractory, locally advanced, or metastatic differentiated thyroid carcinoma. Prior to 2015, sorafenib, a multitargeted tyrosine kinase inhibitor, was the only approved treatment and was associated with a median progression-free survival (PFS) of 11 months and overall response rate (ORR) of 12% in a phase III trial. Lenvatinib,...
متن کاملPostoperative Radioactive Iodine for Differentiated Thyroid Cancer: A Historical Perspective
Radioactive iodine has been used in differentiated thyroid cancer for postoperative thyroid remnant ablation for several decades, yet its indications remain controversial. Because the potential administration of postoperative RAI plays an important role in surgical decision-making, understanding the current indications for postoperative RAI is critical in the global management of differentiated...
متن کاملPatient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments
Background. The aims of this study were to assess patients' preferences to wait or start systemic treatment and understand how patients would make tradeoffs between certain severe adverse events (AEs) and additional months of progression-free survival (PFS). Materials and Methods. Adults in France, Germany, and Spain with a diagnosis of DTC and who have had at least one RAI treatment completed ...
متن کاملExtremity Radioactive Iodine Uptake on Post-therapeutic Whole Body Scan in Patients with Differentiated Thyroid Cancer
Objective(s): We investigated a frequency of lower extremity uptake on the radioactive iodine (RAI) whole body scan (WBS) after RAI treatment in patients with differentiated thyroid cancer, in order to retrospectively examine whether or not the frequency was pathological. Methods: This retrospective study included 170 patients with thyroid cancer, undergoing RAI treatment. Overall, 99r (58%) an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Medical Oncology
سال: 2014
ISSN: 1758-8359,1758-8359
DOI: 10.1177/1758834014548188